Search for a trial

An open-label, multi-center, expanded access study of parireotide s.c. in patients with Cushing's disease (CSOM230B2406) (SEASCAPE)

Primary objective: Safety.Secondary objective: Efficacy.

Randomized double blind multi-centre study of the effects on low-dose pegvisomant treatment in acromegalic subjects in whom the IGF1 levels has been normalized by long-acting somatostatin analogues

Primary Study Objective:To assess the efficacy and safety of the co-administration of low-dose pegvisomant (40 mg, administered via subcutaneous injection given once a week) and long-acting somatostatin analogs (administered once monthly) on the…

The three hit hypothesis of psychopathology revisited in a human model exposed to transient endogenous glucocorticoids excess: patients treated for Cushing's syndrome

To understand, from the perspective of the 3-hit hypothesis of psychopathology, individual differences in the neuropsychiatric outcome of previous glucocorticoid (GC) excess in treated Cushing patients.

A prospective trial with ketoconazole and octreotide combination therapy for treatment of Cushing*s disease.

The primary endopoint is to determine whether ketoconazole/octreotide combination therapy, followed by octreotide monotherapy, is an effective treatment for Cushing's disease. Secundary endpoints address the effects of this therapy on bone…

Growth hormone deficiency in patients in long-term remission of adrenal Cushing's syndrome

To assess the presence of GH deficiency in patients who are in long-term remission of Cushing*s syndrome due to adrenal adenoma.

Predictive value of baseline and stimulated serum IGF-1 and IGFBP-3 during a dose-escalation IGF-1 generation test with NutropinAq for the 1 year growth response to growth hormone (GH) therapy in short children with low IGF-1 and a normal GH peak in a provocation test

Primary objective: Assessment of the value of the short-term (2 weeks) response of IGF-I (peak IGF-I SDS) to GH in a dosage of 1.4 mg/m2/day (as part of a dose-escalation IGF-I generation test) in comparison to baseline IGF-I to predict the 1 year…

Predictive diagnostic study on the short-term metabolic effects of recombinant human Growth Hormone treatment in growth hormone deficiency and small for gestational age children.

The primary objective of this study is to assess the relation between the short term metabolic changes after start of rhGH therapy and the long term change in height SDS after one year of treatment. Secondly, we want to assess the effects of GH on…

(f)MRI parameters and the relation with cognitive and emotional dysfunction in patients after treatment for M. Cushing and a comparison with patients with anxiety and depression

To study the effects of transient severe endogenous stress hormone exposure on the structure and functioning of brains circuitry regulating emotion, and the association with cognition and psychopathological symptoms.

Facial analysis in acromegaly: a cross sectional study of persistent craniofacial changes after remission.

To investigate the differences in facial analysis, between patients with acromegaly, being in remission, and healthy subjects, and to investigate the changes in relational proportions between these facial structures.

A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing*s disease

To assess the efficacy and safety of two Pasireotide LAR regimens in CD patients.

A randomized double blind cross-over trial of the effects of low dose and high dose hydrocortisone replacement therapy on cognition, quality of life, metabolic profile and somatosensation in patients with secondary adrenal insufficiency

The aim of this study is to investigate whether a physiologically low hydrocortisone (HC) dose is better for cognition as compared to a high hydrocortisone dose. In addition, quality of life, metabolic profile and somatosensation will be described…